Navigation Links
Onconase has Potential as Chemopreventive Agent in Mesothelioma,,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting

BLOOMFIELD, N.J., April 18, 2007 /PRNewswire-FirstCall/ -- ONCONASE (ranpirnase), Alfacell Corporation's lead drug candidate, may have potential as a chemopreventive agent, according to world-renowned mesothelioma researcher Michele Carbone M.D., Ph.D., at this week's American Association for Cancer Research (AACR) Annual Meeting.

In a series of poster presentations, Dr. Carbone highlighted the growing worldwide problem of asbestos exposure and its link to malignant mesothelioma. Dr. Carbone presented data that show the early detection in patients at high risk for developing malignant mesothelioma is becoming more prevalent via the presence of certain biological markers in blood samples. Furthermore, he pointed out that ONCONASE's favorable toxicity profile and its well-documented mechanism of action, which directly affects the pathway that has been shown to cause asbestos carcinogenesis, position ONCONASE for potential early administration to populations "at-risk" for mesothelioma. If clinically validated, such a new approach might enable physicians to use ONCONASE as a chemopreventive agent to potentially prevent the onset of mesothelioma, or reduce the doses of cytotoxic agents needed in those patients who develop the disease.

"The potential of ONCONASE as an early first-line preventative treatment for mesothelioma is an exciting development that we plan to investigate through clinical trials," said Dr. Carbone. "With approximately more than 25 million asbestos exposure cases reported worldwide, we believe that ONCONASE might play a greater role in the treatment protocols for a much larger population than was originally envisioned for this dismal disease."

Dr. Carbone is a professor and director of the thoracic oncology program as well as a clinical professor of pathology with the University of Hawaii's Cancer Research Center of Hawaii, and chairman of the Alfacell Thoracic Advisory Boar d. Previously, Dr. Carbone was Director of the Thoracic Oncology Program at Loyola University in Chicago, where he is also a tenured Professor at the Cancer Center, Department of Pathology. He also held scientific and academic positions at the National Institutes of Health (NIH), and at the University of Chicago.

Kuslima Shogen, Alfacell's chairman and chief executive officer, added: "Dr. Carbone is recognized as one of the world's leading researchers in mesothelioma. His remarks about ONCONASE at the AACR Annual Meeting reflect the interest of the international medical community in expanding the potential uses of ONCONASE."

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar ex pressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact:                      Investor Contact:

    David Schull or Wendy Lau           Andreas Marathovouniotis

    Noonan Russo                        Noonan Russo

    212-845-4271                        212-845-4253

               

    

david.schull@eurorscg.com andreas.marathis@eurorscg.com wendy.lau1@eurorscg.com

CONTACT: David Schull or Wendy Lau, +1-212-845-4271, or, or , or AndreasMarathovouniotis, +1-212-845-4253, or , all ofNoonan Russo david.schull@eurorscg.com wendy.lau1@eurorscg.com andreas.marathis@eurorscg.com

Web site: http://www.alfacell.com/http://www.noonanr usso.com/

Ticker Symbol: (NASDAQ-NMS:ACEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
2. Researchers Identify Intracellular Pathway of Alfacells Onconase
3. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
4. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
5. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. New Information on the Potential of Plasmin Shared at ISTH Congress
8. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
9. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
10. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
11. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016  Replikins Ltd. today reported initial promising results in animal trials of its ... http://photos.prnewswire.com/prnh/20160505/364345 ... ... ... specimens recorded on Pubmed. The analysis identified the highest gene Replikin Counts in Zika ...
(Date:5/5/2016)... -- Progra m m e ... , s mosquito in Cayman Islands ... by 96 %   Oxitec and the Cayman Islands ... Aedes aegypti, the dangerous mosquito that spreads dengue, Zika and chikungunya, ... Grand Cayman .  MRCU, a global leader in mosquito control, is planning ...
(Date:5/5/2016)... May 5, 2016 ... addition of the  "Europe Thrombocythemia Market ...  report to their offering.  ... , ,The latest research Europe Thrombocythemia ... 2016, provides comprehensive insights into Thrombocythemia ...
Breaking Medicine Technology:
(Date:5/6/2016)... Florida (PRWEB) , ... May 06, 2016 , ... ... their heads as they try to get rid of the bugs and keep them ... trying to figure out how to protect their kids and their homes from the ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... of a master charity program created to support and assist the people of ... days, working closely with nonprofit organizations and community leaders. Their desire is to ...
(Date:5/6/2016)... Tenn. (PRWEB) , ... May 06, 2016 , ... The joy associated with Mother’s Day ... their lives in neonatal intensive care units (NICUs) across the country. For the first time ... joining together to honor these women who spend their Mother’s Day beside a crib surrounded ...
(Date:5/6/2016)... ... 2016 , ... US Sports Camps has collaborated with State Rugby Organization (SRO), ... this summer. Employing world-class rugby figures, including former Team USA players and college coaches, ... key fundamentals, match play, fitness and more. , “US Sports Camps is honored to ...
(Date:5/6/2016)... ... May 06, 2016 , ... Bluvault ... latest implementation service offering for global clients of Coupa ( Coupa Software ) ... Bluvault’s Integration Service is a key component in the suite of innovative implementation ...
Breaking Medicine News(10 mins):